Search research articles
Contact Us
Filters
Showing results (41-50 of 61) with videos related to
Page
of 7
Sort By:
Ejhaem
|
July 18, 2022
RAS mutation leading to acquired resistance to dabrafenib and trametinib therapy in a multiple myeloma patient harboring BRAF mutation
Baptiste Le Calvez, Yannick Le Bris, Guillaume Herbreteau, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
March 26, 2013
Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis
Amandine Le Bourgeois, Catherine Mohr, Thierry Guillaume, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
April 1, 2019
Influence of Donor Type (Sibling versus Matched Unrelated Donor versus Haploidentical Donor) on Outcomes after Clofarabine-Based Reduced-Intensity Conditioning Allograft for Myeloid Malignancies
Louise Bouard, Thierry Guillaume, Pierre Peterlin, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
November 28, 2018
Deauville Scores 4 or 5 Assessed by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Early Post-Allotransplant Is Highly Predictive of Relapse in Lymphoma Patients
Louise Bouard, Caroline Bodet-Milin, Clément Bailly, et al.
Ejhaem
|
July 6, 2021
Safety and immunogenicity of a first dose of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic stem-cells recipients
Patrice Chevallier, Marianne Coste-Burel, Amandine Le Bourgeois, et al.
European Journal of Haematology
|
April 4, 2017
Is allogeneic stem cell transplantation for myelofibrosis still indicated at the time of molecular markers and JAK inhibitors era?
Elsa Lestang, Pierre Peterlin, Yannick Le Bris, et al.
Transplantation
|
July 17, 2012
Is ASCT with TBI superior to ASCT without TBI in mantle cell lymphoma patients?
Pierre Peterlin, Christophe Leux, Thomas Gastinne, et al.
British Journal of Haematology
|
October 21, 2021
Interest of a third dose of BNT162b2 anti-SARS-CoV-2 messenger RNA vaccine after allotransplant
Amandine Le Bourgeois, Marianne Coste-Burel, Thierry Guillaume, et al.
Transplantation and Cellular Therapy
|
February 26, 2022
B Cell Aplasia Is the Most Powerful Predictive Marker for Poor Humoral Response after BNT162b2 mRNA SARS-CoV-2 Vaccination in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation
Maxime Jullien, Amandine Le Bourgeois, Marianne Coste-Burel, et al.
British Journal of Haematology
|
September 3, 2021
Safety and antibody response after one and/or two doses of BNT162b2 Anti-SARS-CoV-2 mRNA vaccine in patients treated by CAR T cells therapy
Thomas Gastinne, Amandine Le Bourgeois, Marianne Coste-Burel, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 61) with videos related to
Sort By:
Page
of 7
Ejhaem
|
July 18, 2022
RAS mutation leading to acquired resistance to dabrafenib and trametinib therapy in a multiple myeloma patient harboring BRAF mutation
Baptiste Le Calvez, Yannick Le Bris, Guillaume Herbreteau, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
March 26, 2013
Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis
Amandine Le Bourgeois, Catherine Mohr, Thierry Guillaume, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
April 1, 2019
Influence of Donor Type (Sibling versus Matched Unrelated Donor versus Haploidentical Donor) on Outcomes after Clofarabine-Based Reduced-Intensity Conditioning Allograft for Myeloid Malignancies
Louise Bouard, Thierry Guillaume, Pierre Peterlin, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
November 28, 2018
Deauville Scores 4 or 5 Assessed by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Early Post-Allotransplant Is Highly Predictive of Relapse in Lymphoma Patients
Louise Bouard, Caroline Bodet-Milin, Clément Bailly, et al.
Ejhaem
|
July 6, 2021
Safety and immunogenicity of a first dose of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic stem-cells recipients
Patrice Chevallier, Marianne Coste-Burel, Amandine Le Bourgeois, et al.
European Journal of Haematology
|
April 4, 2017
Is allogeneic stem cell transplantation for myelofibrosis still indicated at the time of molecular markers and JAK inhibitors era?
Elsa Lestang, Pierre Peterlin, Yannick Le Bris, et al.
Transplantation
|
July 17, 2012
Is ASCT with TBI superior to ASCT without TBI in mantle cell lymphoma patients?
Pierre Peterlin, Christophe Leux, Thomas Gastinne, et al.
British Journal of Haematology
|
October 21, 2021
Interest of a third dose of BNT162b2 anti-SARS-CoV-2 messenger RNA vaccine after allotransplant
Amandine Le Bourgeois, Marianne Coste-Burel, Thierry Guillaume, et al.
Transplantation and Cellular Therapy
|
February 26, 2022
B Cell Aplasia Is the Most Powerful Predictive Marker for Poor Humoral Response after BNT162b2 mRNA SARS-CoV-2 Vaccination in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation
Maxime Jullien, Amandine Le Bourgeois, Marianne Coste-Burel, et al.
British Journal of Haematology
|
September 3, 2021
Safety and antibody response after one and/or two doses of BNT162b2 Anti-SARS-CoV-2 mRNA vaccine in patients treated by CAR T cells therapy
Thomas Gastinne, Amandine Le Bourgeois, Marianne Coste-Burel, et al.
Page
of 7